BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:A2B543 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of A2B543\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06051695-2311@assetmemo.bio
DTSTAMP:20261121T005320Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:A2B543: Phase 1/2 readout est. (NCT06051695)
DESCRIPTION:A2B543\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated 
 CAR T\, in Participants With Solid Tumors That Express MSLN and Have Lost 
 HLA-A*02 Expression\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/a2b543#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06051695
URL:https://assetmemo.bio/drug/a2b543#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
